Acute Myelogenous Leukemia
The most frequently observed adverse events among patients treated with sorafenib were cytopenias and skin rashes.
There is warranted excitement for AG-221, a drug recently granted fast track designation by the FDA for acute myelogenous leukemia (AML).
The FDA has granted Fast Track designation to AG-221, a first-in-classinhibitor, to treat AML.
Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.
Results from a new study could benefit some children with high-risk AML. A therapeutic regimen that combined the GO with conventional three-drug chemotherapy was associated with improved survival in children with AML who underwent bone marrow transplantation.
At least one nonsynonymous mutation in a gene relevant for pathogenesis seen in nearly all cases
Assessment of minimal residual disease provides prognostic information for children with AML.
Relapse of acute myeloid leukemia (AML) is associated with acquisition of new mutations and clonal evolution.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Nivolumab Monotherapy Provides Long Term Benefit Advanced Melanoma
- Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
- Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy
- Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
- Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer